AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GAgreement Regarding Joint • February 13th, 2020 • New Leaf Biopharma Opportunities II, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Aravive, Inc.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GAgreement Regarding Joint • November 6th, 2018 • New Leaf Biopharma Opportunities II, L.P. • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Proteon Therapeutics, Inc.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GAgreement Regarding Joint • July 24th, 2018 • New Leaf Biopharma Opportunities II, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Versartis, Inc.
AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13GAgreement Regarding Joint • February 13th, 2019 • New Leaf Biopharma Opportunities II, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Aravive, Inc.
